US Lactase Market Outlook and Growth Analysis (2025-2035)
The US lactase market is poised for robust growth through 2035, underpinned by increasing lactose intolerance awareness and an expanding health-conscious consumer demographic. The market, valued at USD 680 Million in 2025, is forecasted to reach USD 1,340 Million by 2035, fueled by the demand for lactose-free dairy products, dietary supplements, and pharmaceutical applications. Innovations in immobilized lactase technology and e-commerce distribution further support accelerated adoption, while regulatory developments ensure product safety and compliance.
Latest Market Dynamics
Key Drivers
- Rising awareness of lactose intolerance and digestive health among US consumers is significantly boosting demand for lactase in food and beverage products. For example, in 2024, Novozymes launched advanced lactase enzymes customized for the US dairy industry, targeting improved milk digestibility.
- Growth of lactose-free product lines by major FMCG brands, such as Danone and General Mills, is driving market expansion. Companies are investing in enhanced enzyme formulations to widen their lactase-based portfolios and achieve higher consumer satisfaction.
Key Trends
- E-commerce expansion, with online retail increasingly becoming a preferred distribution channel for lactase supplements and lactose-free products, is a leading trend. DuPont (IFF) reported a 20% rise in online lactase enzyme sales in early 2024, leveraging direct-to-consumer platforms.
- Shifts towards plant-based and clean-label solutions in lactase production are shaping the market. In 2025, DSM introduced eco-label lactase enzyme products, tapping into the sustainability trend within US food manufacturing.
Key Opportunities
- Product innovation targeting lactase-stabilized infant nutrition and high-performance sports supplements is a core opportunity. Kerry Group announced novel, shelf-stable lactase forms for infant formula in June 2024.
- Adoption of immobilized lactase technology for higher efficiency and lower production costs offers avenues for scaling. Chr. Hansen invested in advanced bioprocessing facilities for immobilized enzymes in Q2 2024.
Key Challenges
- Stringent regulatory pathways for enzyme approval pose challenges. In 2024, Advanced Enzyme Technologies faced extended FDA review timelines for new product launches.
- Fluctuations in raw material supply and price volatility, especially for microbial sources, complicate procurement and stability in lactase manufacturing. Amano Enzyme reported cost escalations due to global supply chain constraints.
Key Restraints
- Limited consumer awareness in rural and smaller urban areas remains a restraining factor, slowing the uptake of lactase-based products among certain demographics.
- Competition from alternative digestive enzymes and evolving biotechnology solutions presents a restraint to lactase market share growth, highlighted by Senson’s 2025 launch of multi-enzyme blends targeting lactose maldigestion.
US Lactase Market Share by Type, 2025
In 2025, the US lactase market is segmented by product type, with dry lactase leading at 40%, widely used in packaged foods, bakery, and dietary supplements for its stability and ease of storage. Liquid lactase commands 35%, preferred by the dairy industry for rapid milk conversion. The capsule/tablet segment secures a 25% share, benefiting from direct-to-consumer supplement trends. The dominance of these types reflects the blend of industrial and direct consumer demand for effective lactose digestion solutions.
US Lactase Market Share by Applications, 2025
By application, the food & beverage industry holds the largest market share at 46%, driven by surging demand for lactose-free dairy and processed food products. Dietary supplements account for 33% as consumers seek targeted digestive health aids. Pharmaceuticals comprise 21%, addressing medical needs for lactose intolerance and related gastrointestinal issues. This segmentation underscores the crucial role of lactase in both daily nutrition and therapeutic applications.
US Lactase Market Revenue (USD Million), 2020–2035
The US lactase market demonstrated consistent revenue growth from 2020 through 2035, rising from USD 480 Million in 2020 to an estimated USD 1,340 Million in 2035. This trajectory is underpinned by a CAGR of 10.2% across the forecast period, reflecting sustained consumer interest in lactose-free and gut health solutions. Steady market expansion can be attributed to growing application versatility, channel diversification, and product innovations by key industry players.
US Lactase Market YOY Growth (%), 2020–2035
Year-over-year growth rates for the US lactase market averaged between 8% and 11% throughout the period. The highest surge was noted between 2020 and 2025, coinciding with strong awareness drives and the expansion of lactose-free portfolios. From 2025 onwards, growth moderates but remains robust, sustained by ongoing innovations and expanded applications in both supplements and processed foods.
US Lactase Market Regional Share (%), 2025
Regionally, the Northeast commands the highest US lactase market share at 38% in 2025, attributed to dense urban centers and higher health product consumption. The Midwest follows at 34%, with a robust dairy industry leveraging lactase enzymes. The South and West split the remaining 28%, with emerging demand from expanding urban populations. Regional distribution reflects both production hubs and diverse consumer demand patterns across the country.
US Lactase Market Player Share (%), 2025
The US lactase market remains moderately consolidated, with Novozymes leading at 21%, supported by broad product portfolios and established industry partnerships. DuPont (IFF) holds a 17% share, leveraging technological innovation. DSM accounts for 13%, due to extensive R&D. The remaining 49% is shared among numerous specialty and regional players, highlighting both established dominance and opportunities for new entrants. US Lactase Market Buyer Share (%), 2025
Industrial food manufacturers represent the largest buyer group in 2025 with 45%, utilizing lactase for producing lactose-free and reduced-lactose products. Pharmaceutical companies hold a 27% share, focusing on health applications. Direct consumers, spurred by online and retail supplement sales, represent 28%, indicating a growing self-care trend. This buyer landscape reinforces the necessity of catering lactase products to both industrial and end-user needs.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | USD Million |
| Regions | Northeast, Midwest, South, West |
| Segments | By Type (Liquid, Dry, Granulated, Tablet, Capsule, Gel), By Application (Food & Beverage, Pharmaceutical, Dietary Supplements, Animal Feed, Infant Nutrition, Others), By Distribution Channels (Online Retail, Supermarkets/Hypermarkets, Pharmacies, Specialty Stores, Direct Sales, Others), By Technology (Free Lactase, Immobilized Lactase, Enzyme Membrane Reactors, Microbial Lactase Technology, Membrane Reactor Technology, Encapsulation Technology), By Organization Size (Small, Medium, Large) |
| Players | Novozymes, DuPont (IFF), DSM, Amano Enzyme, Kerry Group, Senson, Chr. Hansen, Advanced Enzyme Technologies, Specialty Enzymes & Probiotics, Enmex, Mitushi Pharma, Bio-Cat, Zytex, Connell, Nature BioScience |
Key Recent Developments
- June 2024: Novozymes launches high-efficiency lactase enzyme for industrial dairy in the US, improving lactose removal speed and yield.
- July 2024: Kerry Group unveils microencapsulated lactase for infant formula, enhancing shelf stability and integration.
- August 2024: DSM releases plant-based lactase enzymes with eco-label certification, responding to growing sustainability demands.
- September 2024: DuPont (IFF) partners with e-commerce leaders to expand direct-to-consumer lactase supplement offerings.
- October 2024: Chr. Hansen opens a new bioprocessing plant in the US focused on advanced immobilized enzyme technology development.
